With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Novo Nordisk A/S (NYSE:NVO) is one of the Reddit Stocks with the Highest Upside Potential. On August 6, the company stated ...

On Friday, Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety ...

Amycretin differs from other drugs though in also mimicking a second hormone, amylin, which is responsible for helping to regulate blood sugar levels and slowing gastric emptying, prompting the ...

WEDNESDAY, Sept. 11, 2024 (HealthDay News) -- An experimental weight-loss pill appears to help people quickly shed pounds, a new study says. People who took the drug amycretin lost up to 13% of ...

Amycretin is being developed for subcutaneous and oral administration. Shares of this Denmark-based company gained 2.95% on June 12, following the announcement.

PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to ...

Novo Nordisk (NVO) says its novel obesity drug, amycretin, shows promising results with up to 24% of weight loss in a Phase 1/2 trial. Read more here.

Amycretin trial showed weight loss of 9.7% to 22% over 36 weeks at varying doses, compared to weight gain with placebo. Common side effects were mild-to-moderate gastrointestinal issues, aligning ...